February 16, 2026 | HCP Digital Engagement, HCP experience, Healthcare Digital Experience, Life Sciences Innovation, Pharma Digital Strategy
We’re proud to share Graphite’s 2026 research report. An in-depth look at how healthcare professionals experience digital engagement with life sciences today, and where the value gap is widening.

In The value gap: What HCPs want from digital pharma in 2026, we uncover the three dimensions of value that now define meaningful digital engagement: Relevance, Utility and Usability.
Digital is no longer an emerging channel. It is a primary interface between pharma and HCPs — shaping how information is accessed, how clinical decisions are supported and how trust is built over time.
Our independent research with 225 senior clinicians across the UK, USA and Germany reveals a clear pattern:
Digital engagement is embedded.
Attention is selective.
Value is decisive.
The challenge is relevance.
65% say they have reduced or stopped engaging with a pharma company as a direct result of poor digital experiences. Repetitive content. Friction-filled platforms. Promotional tone. Slow access. Gated information.
This disconnect between digital activity and perceived value is what we describe as the value gap.
Across markets and specialties, three dimensions consistently determine whether digital engagement earns attention:
Relevance
Content that reflects clinical context, speciality and patient population — with greater control over what is received and when.
Utility
Digital that supports real clinical tasks: decision-making, patient conversations, access to evidence and practical resources.
Usability
Low-effort, consistent experiences that respect time and reduce friction across devices and touchpoints.
The findings also highlight a significant shift in expectations. HCPs increasingly prefer on-demand, self-directed engagement over interruptive outreach. Trust is shaped not just by the information provided, but by how clearly, transparently and efficiently it is delivered.
The path forward is not more digital.
It is more meaningful digital.
Download your copy here:
This content was provided by Graphite Digital
Company Details
Latest Content from Graphite Digital
At Graphite, we regularly carry out first-hand research with healthcare professionals (HCPs) to understand how they interact with digital experiences in practice. When you combine those conversations with wider sector...
In pharma, the challenge is no longer understanding what HCPs want from digital. It’s delivering it consistently. In this webinar, we explored what needs to change inside organisations to make...
Our research shows that healthcare professionals are not disengaging from pharma digital. They are becoming more selective about the experiences that earn their attention. To explore what this means for...
How can pharma teams scale AI safely across channels? In this session, Ed Hart and Nicolas Barcza explore why strong Design Systems are the foundation for making AI operational, compliant...
We’re proud to share Graphite’s 2026 research report. An in-depth look at how healthcare professionals experience digital engagement with life sciences today, and where the value gap is widening.
As pharma organisations invest extensively in creating engaging content, the onboarding process must not be overlooked. Seamless onboarding is the key to ensuring that HCPs not only meet regulatory standards,...
What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der Heiden (AstraZeneca) argued it starts with design systems. This quick...
Clicks and engagement only tell part of the story. In this webinar, pharma leaders discuss how to move beyond traditional KPIs to measure real impact and ROI from digital and...
Creating great digital experiences in pharma isn’t easy, but progress doesn’t always need to come from big projects or budgets. Here are 5 common challenges that leading digital teams are...
Download your copy of our latest pharma white paper, exploring the latest digital trends, challenges and opportunities in pharma.
